^
    1d
    Impact of Budesonide on Incidence of ≥ Gr2 Diarrhea in Multiple Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplant (clinicaltrials.gov)
    P2, N=120, Suspended, University of Utah | Recruiting --> Suspended | Trial primary completion date: Jan 2026 --> May 2026
    Trial suspension • Trial primary completion date
    |
    CD34 (CD34 molecule)
    1d
    A Study of Inotuzumab Ozogamicin in Chinese Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P4, N=44, Completed, Pfizer | Active, not recruiting --> Completed
    Trial completion
    |
    CD22 (CD22 Molecule)
    |
    CD22 positive
    |
    Besponsa (inotuzumab ozogamicin)
    1d
    Bio-Synthesis of TiO2 and Ag-TiO2 Nanoparticles using Aegle marmelos Seed Extract and their Potential Efficacy Investigation in Human Leukemic Cell Proliferation, Inflammation, and Oxidative Stress. (PubMed, Biol Trace Elem Res)
    Furthermore, the same was confirmed by histopathological examination; TiO₂ and Ag-TiO₂ NPs mitigate tissue damage and inflammation and also showed hepatoprotective properties. In conclusion, both TiO2 and Ag-TiO2 NPs exhibit strong anti-cancer, antioxidant, and anti-inflammatory properties in both in vitro and in vivo conditions.
    Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • CRP (C-reactive protein)
    1d
    Evaluation of multi-antigen targeting ADCC strategies in pediatric BCP-ALL. (PubMed, J Immunother Cancer)
    CD24 therefore emerged as an effective target in BCP-ALL, and the combination of CD24 and CD123 as a potential effective double-targeting strategy. The combination of different recognition modalities (eg, a CAR and CD16) should be tested to determine whether it provides synergistic cytotoxic activity in triple targeting.
    Journal
    |
    CD123 (Interleukin 3 Receptor Subunit Alpha) • CD24 (CD24 Molecule) • IL3RA (Interleukin 3 Receptor Subunit Alpha) • ADAM10 (ADAM Metallopeptidase Domain 10) • ADAM8 (ADAM Metallopeptidase Domain 8)
    |
    Blincyto (blinatumomab) • Besponsa (inotuzumab ozogamicin)
    1d
    Analysis of peripheral blood monocyte subsets in chronic myelomonocytic leukemia: a single-center study (PubMed, Zhonghua Xue Ye Xue Za Zhi)
    Subsequent ROC curve analysis of this cohort identified a cut-off value for the MO1 subset of 97.55% [Area Under the Curve (AUC) =0.661, P=0.027], which aligns with the WHO criteria. Peripheral blood monocyte subset analysis, particularly MO1 subset analysis, can effectively assist in CMML diagnosis, but exclusion of inflammatory conditions is required.
    Retrospective data • Journal
    |
    CD14 (CD14 Molecule)
    1d
    Incidence and associated factors of tyrosine kinase inhibitor withdrawal syndrome and psychological issues in patients with chronic-phase chronic myeloid leukemia after therapy discontinuation (PubMed, Zhonghua Xue Ye Xue Za Zhi)
    Older age at discontinuation and longer TKI therapy duration or DMR duration are significantly associated with TKI withdrawal syndrome. Higher education level and TKI discontinuation due to pregnancy or adverse events are significantly associated with psychological issues.
    Retrospective data • Journal
    |
    ABL1 (ABL proto-oncogene 1)
    1d
    The relationship of dietary folate, folic acid, and childhood cancer. (PubMed, Curr Probl Pediatr Adolesc Health Care)
    The overall evidence supports the continued promotion of adequate maternal folate intake. Future research should prioritize causal inference methods, epigenome-wide analyses, and greater inclusion of underrepresented populations to clarify the role of folate in childhood cancer etiology.
    Review • Journal
    |
    IGF2 (Insulin-like growth factor 2) • MTHFR (Methylenetetrahydrofolate Reductase)
    1d
    Fixed-duration ibrutinib-venetoclax with MRD-guided ibrutinib-obinutuzumab intensification in first-line chronic lymphocytic leukaemia (HOVON 158/NEXT STEP): primary analysis of a multicentre, open-label, phase 2 trial. (PubMed, Lancet Haematol)
    An intensification strategy guided by response and MRD deepened remissions in individuals with residual disease and spared early responders further treatment. This approach merits further study as an alternative to fixed-duration triplet therapy.
    P2 data • Journal
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Venclexta (venetoclax) • Imbruvica (ibrutinib) • Gazyva (obinutuzumab)
    1d
    Phosphorylation at S1288 of Leukemia Associated RhoGEF (LARG/ARHGEF12) induces plasma membrane localization and promotes binding and activation of RhoA. (PubMed, J Biol Chem)
    Moreover, GBM tissue samples showed LARG S1288 phosphorylation and RhoA-GTP-bound RhoA. Elucidating the regulatory mechanisms governing this process is crucial for the development of LARG-targeted therapeutic interventions.
    Journal
    |
    RHOA (Ras homolog family member A) • EGF (Epidermal growth factor) • RPS6KA3 (Ribosomal Protein S6 Kinase A3)
    1d
    Radiomic signatures to estimate survival in patients with advanced hepatocellular carcinoma treated with sorafenib: Cancer and Leukemia Group B 80802 (Alliance). (PubMed, ESMO Open)
    OS can be accurately predicted in patients with HCC receiving sorafenib by combining certain radiomics features with clinical metadata, centered primarily on baseline characteristics.
    Journal
    |
    AFP (Alpha-fetoprotein)
    |
    sorafenib • doxorubicin hydrochloride
    1d
    INO-CD22: ItaliaN Observational Study of Patients With Acute Lymphoblastic Leukemia Treated With Anti-CD22 Immunoconjugate (clinicaltrials.gov)
    P=N/A, N=84, Completed, Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | Recruiting --> Completed | N=120 --> 84
    Trial completion • Enrollment change
    1d
    STAIR: STop and Restart Acalabrutinib In fRail Patients With Previously Untreated Chronic Lymphocytic Leukemia (clinicaltrials.gov)
    P2, N=160, Active, not recruiting, French Innovative Leukemia Organisation | Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2026 --> Aug 2025
    Enrollment closed • Trial primary completion date
    |
    TP53 (Tumor protein P53) • IGH (Immunoglobulin Heavy Locus)
    |
    TP53 mutation • IGH mutation
    |
    Calquence (acalabrutinib)